secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001104659-24-129619
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study
-------------------------------------------------------------------------------

- Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.
- Study evaluates lead candidate for Alzheimer's disease; no specific data points disclosed in the 8-K body.
- Filing dated December 18, 2024; presentation likely includes efficacy/safety findings but details are unreadable.
- Company undertakes no obligation to update the materials; investor attention should review the full presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/0001104659-24-129619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/tm2431405d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer